Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Cytotoxicity testing

Cell viability or cytotoxicity assessments are based on cellular functions that are particularly sensitive to toxic drugs, and as such provide convenient in vitro high-throughput screens (HTS) for comparing relative toxicities of a drug. And primary hepatocytes and/or hepatic cell lines are routinely used given that the liver is the target of most orally delivered drug toxicities.

Sygnature’s Cell Viability assay is a homogenous method that uses the hepatoma cell line, HepG2 and uses a 96-well microtiter plate format to enable higher throughput screening of test compounds. The assessment involves determining the number of viable cells in culture, based upon the quantitation of an endpoint, namely resorufin (Figure 1), a pink fluorescent product of resazurin which signals the presence of metabolically active cells.

Briefly, the assay involves exposing live cells with functioning mitochondria to a set of test compounds and controls for a period of up to 24, 48 or 72 hours. At the end of this incubation 1 mM of Resazurin is added directly to cells cultured in serum-supplemented medium followed by a 4 hour incubation. The fluorescence of resorufin is then detected. Vehicle and digoxin are included as the negative and positive controls, respectively.

Typical pharmacokinetic profiles after a single intravenous (IV) or oral (PO) bolus.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.